Cargando…

FoxP3- and CD8-positive Infiltrating Immune Cells Together Determine Clinical Outcome in Colorectal Cancer

Immune cells are known to affect clinical outcome in colorectal cancer. Subsets of immune cells can both support and inhibit immunological interaction with tumor cells. We examined the clinical impact of T cells that are supposed to be responsible for the down regulation of a T cell response: regula...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeestraten, Eliane C. M., Van Hoesel, Anneke Q., Speetjens, Frank M., Menon, Anand G., Putter, Hein, van de Velde, Cornelis J. H., Kuppen, Peter J. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601218/
https://www.ncbi.nlm.nih.gov/pubmed/21732187
http://dx.doi.org/10.1007/s12307-011-0071-x
_version_ 1782475735162683392
author Zeestraten, Eliane C. M.
Van Hoesel, Anneke Q.
Speetjens, Frank M.
Menon, Anand G.
Putter, Hein
van de Velde, Cornelis J. H.
Kuppen, Peter J. K.
author_facet Zeestraten, Eliane C. M.
Van Hoesel, Anneke Q.
Speetjens, Frank M.
Menon, Anand G.
Putter, Hein
van de Velde, Cornelis J. H.
Kuppen, Peter J. K.
author_sort Zeestraten, Eliane C. M.
collection PubMed
description Immune cells are known to affect clinical outcome in colorectal cancer. Subsets of immune cells can both support and inhibit immunological interaction with tumor cells. We examined the clinical impact of T cells that are supposed to be responsible for the down regulation of a T cell response: regulatory T cells or Tregs. The study population (n = 76) consisted of a random population of colorectal cancer patients who did not receive any (neo-) adjuvant therapy, with a median follow-up time of 7.3 years (range 0.1–23.1 years). Expression of FoxP3 was used as an immunohistochemical marker to identify Tregs. We considered FoxP3+ cells present in tumor stroma and tumor epithelium separately, and related results to clinical outcome and to data on CD8+ immune cell infiltration that we previously obtained in the same patient cohort. All samples showed presence of Foxp3+ cells and in the majority of the patients (85.5%) these cells were also present in the tumor epithelial compartment. A relative high level of Foxp3+ cells in the tumor epithelium was significantly related to down regulation of HLA Class I expression (p-value 0.03). There was a trend, but no significant relation, towards a longer overall survival (p-value; 0.084) and disease-free survival (p-value; 0.073) when high levels of Foxp3+ cells were present in the tumor epithelium. More importantly, the ratio of CD8+/Foxp3+ cells did show a significant correlation with distant-recurrence-free survival. This was the case for both Foxp3+ cells specifically located in the tumor epithelium (p-value 0.024) as well as in the stroma compartment (p-value 0.018). Unfortunately due to the small sample size the ratios did not retain their statistical significance in multivariate analysis. These results provide further evidence that local interactions in the cancer microenvironment between tumor cells and immune cells are not only determined by tumor cell-related factors like HLA expression, but also by interactions among immune cells.
format Online
Article
Text
id pubmed-3601218
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-36012182013-03-19 FoxP3- and CD8-positive Infiltrating Immune Cells Together Determine Clinical Outcome in Colorectal Cancer Zeestraten, Eliane C. M. Van Hoesel, Anneke Q. Speetjens, Frank M. Menon, Anand G. Putter, Hein van de Velde, Cornelis J. H. Kuppen, Peter J. K. Cancer Microenviron Original Paper Immune cells are known to affect clinical outcome in colorectal cancer. Subsets of immune cells can both support and inhibit immunological interaction with tumor cells. We examined the clinical impact of T cells that are supposed to be responsible for the down regulation of a T cell response: regulatory T cells or Tregs. The study population (n = 76) consisted of a random population of colorectal cancer patients who did not receive any (neo-) adjuvant therapy, with a median follow-up time of 7.3 years (range 0.1–23.1 years). Expression of FoxP3 was used as an immunohistochemical marker to identify Tregs. We considered FoxP3+ cells present in tumor stroma and tumor epithelium separately, and related results to clinical outcome and to data on CD8+ immune cell infiltration that we previously obtained in the same patient cohort. All samples showed presence of Foxp3+ cells and in the majority of the patients (85.5%) these cells were also present in the tumor epithelial compartment. A relative high level of Foxp3+ cells in the tumor epithelium was significantly related to down regulation of HLA Class I expression (p-value 0.03). There was a trend, but no significant relation, towards a longer overall survival (p-value; 0.084) and disease-free survival (p-value; 0.073) when high levels of Foxp3+ cells were present in the tumor epithelium. More importantly, the ratio of CD8+/Foxp3+ cells did show a significant correlation with distant-recurrence-free survival. This was the case for both Foxp3+ cells specifically located in the tumor epithelium (p-value 0.024) as well as in the stroma compartment (p-value 0.018). Unfortunately due to the small sample size the ratios did not retain their statistical significance in multivariate analysis. These results provide further evidence that local interactions in the cancer microenvironment between tumor cells and immune cells are not only determined by tumor cell-related factors like HLA expression, but also by interactions among immune cells. Springer Netherlands 2011-07-06 /pmc/articles/PMC3601218/ /pubmed/21732187 http://dx.doi.org/10.1007/s12307-011-0071-x Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Original Paper
Zeestraten, Eliane C. M.
Van Hoesel, Anneke Q.
Speetjens, Frank M.
Menon, Anand G.
Putter, Hein
van de Velde, Cornelis J. H.
Kuppen, Peter J. K.
FoxP3- and CD8-positive Infiltrating Immune Cells Together Determine Clinical Outcome in Colorectal Cancer
title FoxP3- and CD8-positive Infiltrating Immune Cells Together Determine Clinical Outcome in Colorectal Cancer
title_full FoxP3- and CD8-positive Infiltrating Immune Cells Together Determine Clinical Outcome in Colorectal Cancer
title_fullStr FoxP3- and CD8-positive Infiltrating Immune Cells Together Determine Clinical Outcome in Colorectal Cancer
title_full_unstemmed FoxP3- and CD8-positive Infiltrating Immune Cells Together Determine Clinical Outcome in Colorectal Cancer
title_short FoxP3- and CD8-positive Infiltrating Immune Cells Together Determine Clinical Outcome in Colorectal Cancer
title_sort foxp3- and cd8-positive infiltrating immune cells together determine clinical outcome in colorectal cancer
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601218/
https://www.ncbi.nlm.nih.gov/pubmed/21732187
http://dx.doi.org/10.1007/s12307-011-0071-x
work_keys_str_mv AT zeestratenelianecm foxp3andcd8positiveinfiltratingimmunecellstogetherdetermineclinicaloutcomeincolorectalcancer
AT vanhoeselannekeq foxp3andcd8positiveinfiltratingimmunecellstogetherdetermineclinicaloutcomeincolorectalcancer
AT speetjensfrankm foxp3andcd8positiveinfiltratingimmunecellstogetherdetermineclinicaloutcomeincolorectalcancer
AT menonanandg foxp3andcd8positiveinfiltratingimmunecellstogetherdetermineclinicaloutcomeincolorectalcancer
AT putterhein foxp3andcd8positiveinfiltratingimmunecellstogetherdetermineclinicaloutcomeincolorectalcancer
AT vandeveldecornelisjh foxp3andcd8positiveinfiltratingimmunecellstogetherdetermineclinicaloutcomeincolorectalcancer
AT kuppenpeterjk foxp3andcd8positiveinfiltratingimmunecellstogetherdetermineclinicaloutcomeincolorectalcancer